EL7.AI
StocksMedium•23 July 2026•
1 min read

West Pharmaceutical Raises 2026 Guidance Amid Surging GLP-1 Demand

Key Facts

1West Pharmaceutical reported a beat in both earnings and revenue for the second quarter.
2The company raised its 2026 annual guidance citing continued strength in GLP-1 and High-Value Product (HVP) segments.

Amid the rapid global expansion of the obesity and diabetes drug market, West Pharmaceutical reported second-quarter 2026 financial results that surpassed analyst estimates. Consequently, the company raised its full-year adjusted earnings per share guidance to a range of $8.85 to $9.05, up from the previous outlook of $8.40 to $8.75. Annual sales guidance was also revised upward to between $3.345 billion and $3.380 billion, driven by sustained robust demand across its core segments.

This growth is primarily attributed to the High-Value Product (HVP) segment and GLP-1 drug components, with proprietary product sales growing 16.6% to reach $722.6 million. Sales of HVP delivery devices surged by 29.6%, reflecting increased reliance on the company's solutions for biologics and biosimilars. Despite minor impacts from a cyber incident on the contract-manufacturing segment, overall performance remained strong due to the continued strength in GLP-1 elastomers and HVP upgrades.

Looking ahead, the company anticipates third-quarter adjusted earnings between $2.14 and $2.24 per share, exceeding market consensus. Additionally, market participants will watch for broader economic signals such as the Michigan Consumer Sentiment and inflation expectations data due on July 17, 2026, which may influence healthcare sector sentiment.